

A FORMAT TO INSTANTLY TEST hMSCs


RoosterRTP™-hBM-50M-XF | High Volume hMSCs

Ready-to-Print. Ready-to-Seed.
Getting you Right-to-Product Development.

WWW.ROOSTERBIO.COM



RoosterBio®



An MSC reagent for same-day experiments, RoosterRTP is fully-expanded and ready-to-use in various applications without cell culture.

This 50M viable cell MSC format enables product developers and researchers to remove their cell manufacturing process and get right-to-product development. Instead of repeatedly producing 10M to 100M hMSCs, start with a standardized cell population (with consistent PDL) that is translation-ready and clinically-relevant.



Rapidly prototype
tissue designs



Plug & Play as
the cell component
of bioink



Seed directly into tissue
engineering scaffolds,
or incorporate within a
medical device

ROOSTERRTP-hBM-50M-XF BENEFITS

Utilize hMSCs as you would in a commercial environment

- > Thaw and use directly into experiments
- > Does not require sourcing material for large scale production (and cryopreservation) of hMSCs
- > Minimize experimental variability using a standardized hMSC

For rapid integration

- > Minimize time between experiments for accelerated discovery
- > Cost-effective approach | Available at a fraction of typical hMSC cost
- > Transparent and streamlined path to cGMP manufacturing for customer-specific applications

50 Million Thaw-and-Use hMSCs for Product Development

PRODUCT FEATURES

- > 50 million late-passage (PDL 15-17) cryopreserved hBM-MSCs
- > Xeno-free formulation (XFF)
- > Intended Use: Research Use Only
- > Industry-leading functional characterization
- > Preserved critical MSC quality attributes at late-passage
- > Not intended for further subculturing and banking
- > Directly comparable to parent lot
- > Manufactured with scalable processes & cryopreserved using standard, controlled processes
- > Lots released based on viability, plating efficiency, and sterility (see CoA)

READILY STUDY BIOMATERIAL & BIOFABRICATION EFFECTS ON:

Tri-lineage differentiation


Cytokine secretion profile

Inducible immunomodulatory function


CHARACTERIZATION OF ROOSTERRTP™-hBM-50M-XF MSCS

RoosterRTP-hBM-50M-XF MSCs are Directly Comparable to Earlier-Passage XF hBM-MSCs

I. CYTOKINE SECRETION




II. SURFACE MARKER EXPRESSION




III. DIFFERENTIATION & IMMUNOMODULATORY POTENTIAL


(A) Adipogenesis



(B) Osteogenesis



(C) Chondrogenesis



(D) IDO Activity




Fig 1: XF RTP hBM-MSCs (thawed and tested) compared to parent lot XF hBM-MSCs (expanded and tested) show comparable (I) Angiogenic cytokine secretion, (II) Surface marker expression as well as (III) Tri-lineage differentiation and IDO activity at later passages (parent lot data not shown for Tri-lineage differentiation and IDO activity).

AN MSC REAGENT THAT'S READY TO ACCELERATE CELL THERAPY,
TISSUE ENGINEERING AND CELLULAR BIOPRINTING

RoosterBio®

www.roosterbio.com

| www.roosterbio.blogspot.com